XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Note 5 - Restructuring and Other Exit Costs
3 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Restructuring and Related Activities Disclosure [Text Block]

5.

Restructuring and Other Exit Costs

 

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify operational efficiencies, enhance commercial capabilities, and align its cost base and infrastructure with customer needs and its strategic plans. In order to realize these opportunities, the Company undertakes restructuring-type activities from time to time to transform its business. A portion of these transformation activities are considered restructuring costs under ASC 420 Exit or Disposal Cost Obligations and are discussed below.

 

During 2019, the Company initiated a restructuring program to improve operational efficiency and reduce costs which entailed consolidating and downsizing several sites and headcount reductions in Europe and North America. This program was completed in 2021. Restructuring costs under this program were $0.6 million for the three months ended March 31, 2021, substantially all of which have been included as a component of general and administrative expenses.